

October 07, 2022

BSE Limited

P.J. Towers, Dalal Street, Mumbai-400001 Scrip Code: 530239 **National Stock Exchange of India Limited**

"Exchange Plaza", Bandra-Kurla Complex, Bandra (East), Mumbai-400051. Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Intimation of the meeting of the Rights Issue Committee of Board of Directors of Suven Life Sciences Limited ("Company") to be held on Wednesday, October 12, 2022.

Ref.: Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations")

This is further to our intimation dated June 24, 2022 informing approval of the Board of Directors of the Company for issuance of the equity shares of the Company of face value of ₹ 1/- each for an amount not exceeding ₹ 400 crores by way of a rights issue to the eligible equity shareholders of the Company as on the record date in accordance with the provisions of Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, each as amended, and other applicable laws.

For giving effect to the Rights Issue, the Board of Directors of the Company had constituted the Rights Issue Committee to decide terms and conditions of the Rights Issue.

We inform you that a meeting of the Rights Issue Committee of the Board of Directors of the Company will be held on **Wednesday**, **October 12**, **2022** to, *inter alia*, consider and approve the terms and conditions of the rights issue including determination of the issue price and record date for the issuance of equity shares to be offered in the rights issue.

This intimation is issued in terms of Regulation 29(1)(d) of the SEBI Listing Regulations.

This is for your information as also for the information of your members and the public at large.

Thanking you,

Yours faithfully,
For Suven Life Sciences Limited

Shrenik Soni Company Secretary

Suven Life Sciences Limited